

PRESENTATION AGENDA

MINUTES	SESSION / SPEAKER
9:00	Housekeeping and Technical Instructions
9:05	Welcome from the ECD Global Alliance Kathy Brewer <i>President</i>
9:25	Report on ECD Registry and Analysis of Fatigue and Pain in ECD Registry Patients Eli L. Diamond, MD <i>Memorial Sloan Kettering</i>
BASIC SCIENCE	
9:45	Oncogene-Induced Maladaptive Activation of Trained Immunity in the Pathogenesis and Treatment of Erdheim-Chester Disease Giulio Cavalli, MD, Ph.D. <i>IRCCS San Raffaele Scientific Institute, Milan, Italy</i>
10:05	Disturbance of monocyte homeostasis in histiocytosis is close to chronic myelomonocytic leukemia and is correlated with phenotype and disease activity Razanamahery Jerome, MD <i>Pitié-Salpêtrière Hospital, Paris, France</i>
10:25	Novel recurrent mutations in Erdheim-Chester Disease patients identified by whole-exome sequencing and whole-genome sequencing Yu Oyama, MD <i>The University of Tokyo, Tokyo, Japan</i>
10:45	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease Oshrat Rokah, Ph.D. <i>Assuta Medical Center, Tel-Aviv, Israel</i>
CASE STUDIES	
11:05	Dramatic efficacy of Vemurafenib on psychiatric symptoms revealing <i>BRAF^{V600E}</i> Erdheim-Chester Disease Razanamahery Jerome, MD <i>Dijon University Hospital, Dijon, France</i>
11:25	Synchronic Systemic Aggressive Mastocytosis and Langerhans Cell Histiocytosis with <i>BRAF p.N486_P490del</i> André Neder Ramires Abdo, MD <i>Oncology Center at Hospital Alemão Oswaldo Cruz, São Paulo</i>
BREAK – 15 MINUTES	



ORGAN INVOLVEMENT

11:45	Role of vascular endothelial growth factor in Erdheim-Chester Disease Anaïs Roeser, MD <i>Assistance Publique Hôpitaux de Paris, Paris, France</i>
12:05	Kidney involvement in Erdheim-Chester disease: a multicenter cohort study on 195 patients Francesco Pegoraro, MD <i>Meyer University Children's Hospital, Firenze, Italy</i>

TREATMENTS

12:25	Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib Ashley Aaroe, MD <i>MD Anderson Cancer Center, Houston, TX, USA</i>
12:45	Outcomes after discontinuing targeted therapy in ECD and other histiocytoses Eli L. Diamond, MD <i>Memorial Sloan Kettering, New York, NY, USA</i>

Q&A WITH EXPERT PANEL

1:05	Leading physicians in various specialties answer attendee questions.
------	--

INTERNATIONAL UPDATES (PRE-RECORDED)

1:35	<ul style="list-style-type: none">• Brazil – Dr. Andre Abdo• China – Dr. Xin-Xin Cao• England – Dr. Tal Munir	<ul style="list-style-type: none">• Israel - Dr. Roei Mazor• Italy - Drs. Augusto Vaglio & Francesco Pegoraro• The Netherlands - Dr. Jam van Laar
------	---	---

CLOSING

2:10	+ Invitation to join the next meeting in April 2022 + Evaluation + More information
------	---

